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KAJIAN GENOTIP-FENOTIP BAGI TUBEROUS SCLEROSIS COMPLEX 
DALAM KOHORT TERPILIH PESAKIT-PESAKIT MALAYSIA YANG 
MEMPUNYAI MUTASI PADA GEN TSC2 
 
ABSTRAK 
Tuberous Sclerosis Complex (TSC) merupakan penyakit dominan autosomal yang 
dapat dikenalpasti melalui kehadiran hamartomas pada bahagian organ-organ yang 
terjejas. Ia merupakan sindrom yang disebabkan oleh mutasi pada salah satu gen, 
TSC1 atau TSC2. Di sini, analisis mutasi dan hubungkait genotip-fenotip telah 
dilakukan ke atas 30 orang pesakit yang telah dikenalpasti sebagai pengidap TSC 
berdasarkan kriteria klinikal 2012 (Northrup et al. 2013). Manifestasi klinikal para 
pesakit ini pelbagai dan tumor kulit dan otak merupakan manifestasi yang paling 
kerap dijumpai dalam kalangan pesakit. Epilepsi juga merupakan kelaziman dan 
ianya lebih banyak berlaku pada pesakit lelaki berbanding perempuan manakala 
pesakit yang mengalami rencatan akal adalah kurang. TSC tidak mempunyai 
pemilihan terhadap umur, bangsa mahupun jantina. Ianya dapat diperhatikan bahawa 
bilangan manifestasi TSC dalam kalangan pesakit familial adalah kurang berbanding 
pesakit sporadik. Walau bagaimanapun, tiada perbezaan dapat diperhatikan dari segi 
tahap keterukan penyakit tersebut.  Kaedah –kaedah yang digunakan dalam kajian ini 
adalah kromatografi cecair berprestasi tinggi (DHPLC), penjujukan langsung DNA, 
multiplex ligation-dependent probe amplification (MLPA) dan penjujukan amplikon 
menggunakan pelantar Miseq. Mutasi dapat dikenalpasti dalam 22 daripada 30 orang 
pesakit TSC. Dua puluh dua orang (73%) pesakit dikenalpasti mempunyai mutasi 
dalam gen TSC2 manakala lapan (27%) pesakit tidak mempunyai sebarang mutasi 
pada gen TSC2. Terdapat 20 mutasi patogenik berbeza telah ditemui dan sepuluh 
merupakan mutasi baru. Tiga puluh peratus dalah mutasi karut, 25% adalah mutasi 
xvii 
 
missens, 25% adalah penambahan dan penghapusan kecil yang menyebabkan mutasi 
bingkai-ubah, 15% adalah penghapusan besar gen dan 5% adalah mutasi pada tapak 
sambat. MLPA disarankan sebagai kaedah pengesanan mutasi barisan pertama 
diikuti dengan penjujukan amplikon menggunakan pelantar Miseq Illumina. Tiada 
mutasi-mutasi tertentu yang dikenalpasti mempengaruhi tahap keterukan dan/atau 
bilangan manifestasi klinikal TSC. Walau bagaimanapun, penyakit buah pinggang 
polisistik (PKD) telah dikenalpasti dalam pesakit TSC yang mempunyai mutasi 
penghapusan besar gen yang melibatkan gen TSC2 dan berterusan sehingga ke gen 
PKD1. Manakala lebih ramai pesakit rabdomioma jantung yang dikenalpasti 
mempunyai mutasi dalam exon 33-41 pada gen TSC2. Oleh kerana bilangan kes yang 
kecil, manifestasi klinikal dalam kumpulan pesakit yang tidak mempunyai sebarang 
mutasi didapati tidak menunjukkan perbezaan ketara jika dibandingkan dengan 
pesakit yang dikenalpasti mempunyai mutasi pada gen TSC2. 
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GENOTYPE-PHENOTYPE STUDY OF TUBEROUS SCLEROSIS 
COMPLEX IN SELECTED COHORT OF MALAYSIAN PATIENTS WITH 
TSC2 MUTATIONS 
ABSTRACT 
TSC (Tuberous Sclerosis Complex) is an autosomal dominant disorder characterized 
by a widespread hamartomatous lesion in multiple affected organs. It is a syndrome 
caused by mutations in either of these two genes, TSC1 and TSC2. Here, mutation 
analysis as well as genotype-phenotype correlation assessment were done in 37 TSC 
patients. Thirty-seven patients, diagnosed as a case of TSC (either definite or 
possible) based on the 2012 clinical diagnostic criteria (Northrup et al, 2013) were 
included in the studies. TSC clinical manifestations among patients were broad and 
the most common were skin and brain tumours. Epilepsy was also common and was 
seen more in male compared to female patients while frequency of mental retardation 
is low.  There is no age, ethnicity and gender preference of TSC manifestations. It is 
noticeable that familial patients showed less number of clinical features compared to 
sporadic patients although no difference in the severity of the manifestations was 
observed. The method of choice used were denaturing high-performance liquid 
chromatography (DHPLC), direct sequencing, multiplex ligation-dependent probe 
amplification (MLPA) and Amplicon Sequencing using MiSeq Platform. TSC2 
mutations were identified in 22 (73%) of 30 TSC patients while eight (27%) were 
identified with no mutation. Out of 20 different pathogenic mutations, ten were novel. 
30% is nonsense mutations, 25% is missense mutations, 25% is small 
insertion/deletion causing frameshift mutations, 15% is large deletions and 5% is 
splice site error mutation. MLPA was suggested as the first line detection method for 
TSC targeting large duplication and deletion mutations. The second line of mutation 
detection is Illumina MiSeq Amplicon Sequencing platform for detection of small 
xix 
 
mutations. No particular mutations were found to influence severity and/or more 
number of clinical manifestations. However, polycystic kidney disease was identified 
in one case with extended deletion from TSC2 to PKD1 while cardiac rhabdomyoma 
are found more in patients with mutations in exon 33-41 of TSC2 gene. Due to small 
number of study subjects, the clinical manifestations of the group of patients without 
identifiable mutation were not much different from the group of patients with 
identifiable mutations. 
1 
 
CHAPTER ONE 
INTRODUCTION AND LITERATURE REVIEW 
1.1 Introduction on Tuberous Sclerosis Complex  
Tuberous Sclerosis Complex (TSC) is an autosomal dominant disorder characterized 
by a widespread hamartomatous lesion in multiple affected organs. Hamartomatous 
lesions or hamartomas are tumour-like growths and they are also referred as tubers. 
Commonly affected organs include brain, kidney, heart and skin. The genetic multi-
system disorder manifests a broad phenotypic spectrum which includes facial 
angiofibromas, hypomelanotic macules, renal angiomyolipomas, cardiac 
rhabdomyomas, cortical tubers, sub-ependymal giant cell astrocytomas (SEGAs) and 
sub-ependymal nodules (SEN) (Roach et al., 1992).    
  
In 1835, TSC was first found in a male patient who had multiple dots of numerous 
small erythematous papules on his face, depicting the facial angiofibromas (Rayer, 
1835), one of well-known TSC clinical manifestations revised nowadays. Later on, 
cardiac myomas and cerebral sclerosis were found in a newborn baby who died a few 
minutes after birth (von Recklinghausen, 1862). Only in 1880, TSC was given its 
name by Bourneville who had provided a detailed description of the cerebral 
pathology of TSC which he had seen in a patient with seizures, hemiplegia, mental 
disorders and renal cysts (Bourneville, 1880). Later on in 1913, the hereditary nature 
of TSC was reported (Berg, 1913). Since then, numerous studies have been carried 
out and have contributed to more detailed description and characterization of the 
disease. 
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1.2 Diagnostic Criteria 
TSC has no pathognomonic feature which has made it hard to be diagnosed. The 
clinical manifestations and findings of TSC are also highly variable. Some patients 
may suffer from severe symptoms while other patients may have milder 
manifestations or can even appear asymptomatic even between the closely related 
family members. Even so, it is crucial to accurately diagnose the disease for the sake 
of implementation of appropriate medical attention and treatment as well as genetic 
counselling for patients.  
 
Historically, the first attempt on guideline for diagnostic criteria of TSC was made 
by Campbell in 1906 and Vogt in 1908. They proposed diagnostic triad of epilepsy, 
mental retardation and adenoma sebaceum. However, it was too basic that they 
would miss out half of the real number of people with TSC. Since then, a few more 
revisions were made including revision in 1979 by Gomez and another attempt by 
Roach in 1992. Only in 1998, Roach managed to put up systematic and 
comprehensive diagnostic criteria which consisted of a set of major and minor 
features. These features can be clinically diagnosed based on combination of clinical, 
radiological and histopathological findings. It was used since then for diagnosis of 
TSC patients until more recent revision was done in 2012 which has made clinical 
diagnostic criteria of TSC to become even more stringent than before (Northrup et al., 
2013). 
 
There are slight differences between the revision made in 1998 and 2012. In 2012, 
they added other diagnostic criteria by means of genetic testing which was not 
included in previous TSC diagnosis in 1998. It is the most significant change 
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recommended to the diagnosis criteria. On the genetic testing basis, definite TSC 
diagnosis can be made by the identification of pathogenic mutation either in TSC1 or 
TSC2 gene in DNA from normal tissue. A pathogenic mutation is defined as a 
mutation that causes the inactivation of the TSC1 or TSC2 protein and hence 
contributes to the disease development. TSC1 or TSC2 non-pathogenic and 
undecided genetic variations are not included as definite TSC diagnosis (Northrup et 
al., 2013). 
     
There are also a few differences in the major and minor features. Most of the major 
features were refined and put into more detail. The revision in 2012 was made 
focusing on the sensitivity and specificity of TSC diagnosis based on clinical 
presentations of a patient. Some features were rarely identified in TSC patients and 
lack of specificity for TSC. Such features like bone cysts and hamartomatous rectal 
polyps were removed from the diagnosis in the 2012 revision.  Cerebral white matter 
radial migration line was included into the major features under “cortical dysplasia” 
with cortical tubers because both are commonly associated with intractable seizures 
and mental disability in TSC. The comparisons of the two revisions are shown in 
Table 1.1. 
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Table 1.1: Comparison of revision in 1998 by Roach and revision in 2012 by 
Northrup. 
 
 Roach 1998 Northrup 2013 
Diagnosis   
Definite Presence of either two major 
features or one major feature with 
two or more minor features 
Presence of two major features or 
one major feature with two or more 
minor features 
Addition: identification of 
pathogenic mutation either in TSC1 
or TSC2 gene in DNA from normal 
tissue 
Probable Presence of one major feature and 
one minor feature 
Removed 
Possible Presence of either one major 
feature or two minor features or 
more minor features 
Presence of either one major 
feature or two or more minor 
features 
Clinical 
manifestations 
  
Major features Hypomelanotic macules (three or 
more) 
Facial angiofibromas 
Forehead plaque 
Non-traumatic ungula or 
periungual fibroma 
Shagreen patch 
Multiple retinal nodular 
hamartomas 
Cortical tuber 
SEN 
SEGA 
Cardiac rhabdomyoma, single or 
multiple 
Lymphangiomyomatosis 
Renal angiomyolipoma 
Hypomelanotic macules (3 or 
more, at least 5 mm in diameter) 
Angiofibromas (3 or more) or 
fibrous cephalic plaque 
Ungual fibromas (2 or more) 
Shagreen patch 
Multiple retinal hamartomas 
Cortical dysplasias (includes tubers 
and cerebral white radial migration 
lines) 
SEN 
SEGA 
Cardiac rhabdomyoma 
Lymphangioleiomyomatosis 
(LAM)(without other features does 
not meet criteria for definite 
diagnosis) 
Angiomyolipomas (2 or more) 
(without other features does not 
meet criteria for definite diagnosis) 
Minor features Multiple randomly distributed pits 
in dental enamel 
Hamartomatous rectal polyps 
Bone cysts 
Cerebral white matter radial 
“migration tracts” 
Gingival fibromas 
Non-renal hamartomas 
Retinal acromic patch 
Confetti-like skin lesion 
Multiple renal cysts 
Confetti-like skin lesions 
Dental enamel pits (3 or more) 
Intraoral fibromas (2 or more) 
Retinal achromic patch 
Multiple renal cysts 
Non-renal hamartomas 
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1.3 Molecular pathogenesis of Tuberous Sclerosis Complex 
1.3.1 Knudson’s two-hit theory 
The pathogenesis of TSC tumours can be explained by Knudson’s two-hit hypothesis. 
The hypothesis mentions that two mutations or ‘hits’ is necessary for the tumour 
development. The hypothesis predicted that the chance is greater for a carrier of the 
germ line mutation to get the second hit as compared to non-carrier to get the same 
two hits in the same location (Knudson, 1971). Pathogenic germline mutation on 
either one of the TSC tumour suppressor genes may activate the tumour progression 
caused by the second random somatic mutation (eg: loss of heterozigosity). Based on 
Knudson’s two-hit hypothesis, the second somatic mutation abrogates TSC tumour 
suppressor genes function completely by accelerating the effect of the pathogenic 
germline mutation in the first place. 
 
1.3.2 Hamartin and tuberin functions 
The function of hamartin and tuberin alone is still a big mystery. In earlier studies, 
hamartin and tuberin have been shown to be expressed together in most human cell 
types and tissues, including in brain, liver, cardiac muscle, kidney, gut, prostate and 
testes even though they have not been identified to function specifically (Johnson et 
al., 2001). Most studies have figured out that both hamartin and tuberin play role in 
cell proliferation, cell growth, cell adhesion, cell migration as well as protein 
transportation in the cell. 
 
Hamartin, a protein product of TSC1 gene, does not have similarity with any known 
vertebrate protein but hamartin does share significant homology to a 
Schizosaccharomyces pombe putative protein (Sampson, 2003). It is widely 
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expressed and has been identified to have four functioning domains which are a 
putative transmembrane domain (at amino acids 127-144), coiled-coil domain (CCD) 
(at amino acids 719-998), amino acid residues as rho-activating domain (amino acids 
145-510) and amino acid residues as ezrin-radixin-moezin (ERM) family of actin 
binding proteins domain (amino acids 881-1084). The coiled-coil domain is 
necessary for its interaction with tuberin. 
 
Tuberin, the product of TSC2 gene on the other hand consists of seven functioning 
domains which are leucine zipper domain (amino acids 81-98), coiled-coil domain 1 
(CCD1) (amino acids 346-371), coiled-coil domain 2 (CCD2) (amino acids 1008-
1021), transcription activation domain 1 (amino acids 1163-1259), GTPase-
activating protein domain (GAP) (1517-1674), transcription activation domain 2 
(1690-1744) and a calmodulin-binding domain (amino acids 1740-1755) (Povey et 
al., 1994; Krymskaya, 2013; Napolioni and Curatolo, 2008). 
 
The binding domains of these two proteins remained unclear until 2003 (Rosner et 
al., 2003). Individually, hamartin inhibits interaction of tuberin with HERC1 
ubiquitin ligase and stabilizes the protein. The presence of mutation in TSC2 permits 
tuberin interaction with HERC1 ubiquitin ligase even with the presence of hamartin, 
preventing their interaction to form tumour suppressor complex (Chong-Kopera et al., 
2006). Hamartin has also been demonstrated to stabilize and improve the expression 
of tuberin (Benvenuto et al., 2000). 
 
In Drosophila, presence of both hamartin and tuberin had been shown to inhibit cell 
proliferation and eventually cell growth. Abnormal expression of these two proteins 
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on the other hand, caused cell growth and size increment. Both regulate cell cycle 
and hamartin has been found to be highly expressed in the G0 phase of cell cycle. 
Too high hamartin level in the cell will reduce cell proliferation. This inhibition 
process can be carried out by hamartin alone without the presence of tuberin 
(Miloloza et al., 2000). It has also been demonstrated that loss in either hamartin or 
tuberin shortens the G1 phase of cell cycle, eventually causing the cell cycle to 
progress into the S phase, mitosis and finally cell proliferation (Potter et al., 2001; 
Gao and Pan, 2001 and Tapon et al., 2001). Cell cycle progression is initiated by 
cyclin-dependant kinases (CDKs) via protein phosphorylation and the activity of 
CDKs are controlled by CDK inhibitors. The presence of hamartin and tuberin 
stabilized the level of these inhibitors, indirectly causing inhibition of cell cycle 
progression (Miloloza et al., 2002). 
 
Hamartin was found to organise cytoskeleton by its interaction with radixin and 
meiosin. These proteins of ERM families link the actin cytoskeleton to the plasma 
membrane and take part in forming adhesion contacts, lamellipodia and microvilli. 
Hamartin also showed interaction with intermediate neurofilament-L. In a cultured 
cell, cells adhesion was no longer seen when hamartin was inhibited. When hamartin 
was overexpressed, focal adhesions was seen as the result of Rho G-protein 
activation (Lamb et al., 2000). These findings suggest that it has multiple functions 
in adhesion and extension of neurons and ganglia process (Haddad et al., 2002). 
 
There is a recent finding on the function of hamartin by Yasui and colleagues in 2007. 
They identified interaction of NADE, cell death executor that is associated with 
p75NTR (low-affinity neutrophin receptor p75), with hamartin coiled-coil domain in 
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a yeast two-hybrid system. Interaction of the two prevents NADE from proteosomal 
degradation and indirectly induces neuron cells apoptosis. Reduction of NADE was 
seen due to low expression of hamartin, leading to disregulation of neuronal cell 
apoptosis. This finding is likely to be the cause of brain pathology in TSC (Yasui et 
al., 2007). 
 
As for tuberin, it may function in few different signalling pathways due to its 
interesting feature that contains multiple phosphorylation sites of Serine, Threonine 
and Tyrosine. A specific association of a protein, 14-3-3, with phosphorylated 
tuberin has been ruled out. Due to 14-3-3 ability to bind to phosphorylated protein, it 
has been known to be involved in various biological events. Tuberin contains several 
putative binding sites for 14-3-3 protein, AKT-phosphorylated dependent sites on 
Serine residues at position 939, 981 and 1341, and a direct binding site on Serine 
residues at 1210. Interestingly, 14-3-3 protein only binds to phosphorylated tuberin 
and not hamartin. Phosphorylated tuberin bind to 14-3-3 protein thus indirectly 
regulates cell growth by AKT phosphorylation inhibition. They found that 
overexpression of 14-3-3 protein increased phosporylation of S6K1 and 4E-BP1, 
resulting in unusual cell growth (Liu et al., 2002). 
 
Wienecke and Xiao have found that tuberin has specific GAP activity towards Rap1 
and Rab5 (Wienecke et al., 1995 and Xiao et al., 2001). Rap1 and Rab5 are a small 
GTPase cytosolic protein. Rap1 promotes cell division while Rab5 involves in early 
endocytic pathway. GAP activity of tuberin towards Rap1 may inhibit the GTPase 
protein thus inactivate cell division. The interaction of tuberin and Rab5 is consistent 
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with the GAP domain found in tuberin. In cell lacking tuberin, the rate of fluid-phase 
endocytosis was increased and the process was reversed by re-expression of tuberin. 
 
1.3.3 Hamartin-tuberin tumour suppressor complex 
Hamartin’s transmembrane bound domain and two coiled-coil domains are also 
necessary for its interaction with tuberin (van Slegtenhorst et al., 1997 and van 
Selgtenhorst et al., 1998). There is also a report suggesting phosphorylation side 
outside the putative interaction domains are also crucial to possibly initiate the 
interaction of hamartin and tuberin (Aicher et al., 2001). 
 
The actual binding site of hamartin and tuberin was first described in 2003 by Rosner 
and colleagues. The finding illustrated that amino acids 302-430 of hamartin and 
amino acids 1-418 of tuberin are the interacting domains between these two gene 
products (Rosner et al., 2003). Presence of physiological stimuli such as insulin 
triggers the phosphorylation of tuberin at its multiple sites involving Serine and 
Tyrosine residues. This is also said to be one of the key mechanisms for its 
interaction with hamartin thus regulating the formation of tuberin-hamartin protein 
complex. (Johnson et al., 2001 and Mizuguchi et al., 1997). 
 
The first discovery on direct interaction of hamartin and tuberin with one another 
was demonstrated in 1998 by van Slegtenhorst and colleagues. In the study, they 
used three independent methods that showed the same finding of hamartin and 
tuberin relationship in mammalian cells. The interaction was mediated in between 
the two coiled-coil domains of these two proteins. They found that these two proteins 
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co-localized more generally in the cytoplasm when co-transfected in mammalian 
cells (van Slegtenhorst et al., 1997). 
 
The findings later on leads to abundant evidences that both genes act as tumour 
suppressor genes and recent investigation of somatic mutation in a variety of TSC 
hamartomas had strengthened the evidence (Cheadle et al., 2000). Hamartin and 
tuberin binds directly with one another, forming a cytoplasmic protein complex that 
has a stable interaction with stoichiometry of 1:1. This tumour suppressor 
heterodimer has an inhibitory effect on cell growth. The need of both proteins to be 
working together in regulating cell growth has also been demonstrated in Drosophila 
(Potter et al., 2001). The figurative structure of both hamartin and tuberin are shown 
in Figure 1.1.  
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Figure 1.1: Illustrative figure on structure of (A) hamartin and (B) tuberin. Shown 
together are inhibitory phosphorylation site on both protein as well as its respective 
kinase. Site where interaction of both proteins takes place is also shown. GAP 
domain is the domain for RHEB which interacts with mTORC1 pathway (Adapted 
from Astrinidis and Henske et al., 2005, Crino et al., 2006). 
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The most exciting and promising discovery is the function of the heterodimer 
complex formed from the interaction of two proteins as the major regulator for the 
mammalian target of rapamycin (mTOR). mTOR is a major signalling pathway that 
monitor the cellular nutrients and energy level of cells. It regulates various cellular 
processes, including metabolism, growth and proliferation of cells. There are at least 
two different multi-proteins complexes which are mTORC1 and mTORC2. TSC 
complex involves mainly in mTORC1 pathways. 
 
The mechanism by which hamartin-tuberin complex regulates mTORC1 pathway 
lies in the discovery of RHEB (a small G protein of the Ras family, enriched in 
brain) as physiological target for tuberin GTPase-activating protein activity, in vitro 
and in vivo (Zhang et al., 2003). It has been proven that RHEB is important in 
progression of cell cycle as well as cell growth in Drosophila (Plank et al., 1998). 
RHEB stimulates. TSC complex serves as GTPase-activating protein (GAP) for 
RHEB and activation of RHEB into its GTP-bound state triggers the interaction with 
mTORC1 thus stimulating its activity in cells (Long et al., 2005 and Sancak et al., 
2007). 
 
The Ras-like GTPase is activated when bound to GTP. In the presence of hamartin-
tuberin intracellular complex, GTP on RHEB is hydrolised to GDP, inactivating the 
RHEB thus downregulates the mTOR and the downstream pathways. Therefore, 
malfunction of TSC complex due to inactivating mutations will contribute to TSC 
development. 
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There are four key signals for mTORC1 which are growth factors, amino acids, 
oxygen and energy statuses. However, stimulation of mTORC1 by amino acids is 
known to be independent of hamartin-tuberin complex. Even in cells lacking 
hamartin-tuberin complex, stimulation of mTORC1 by amino acids remained 
possible (Nobukuni et al., 2005). General overview of mTOR pathways is shown in 
Figure 1.2. 
 
In the presence of growth factor, canonical insulin and Ras signaling pathways are 
activated, increasing tuberin phosphorylation via three factors which are protein 
kinase B (PKB, also known as AKT), extracellular-signal-regulated kinase 1/2 
(ERK1/2) and p90 ribosomal S6 kinase 1 (RSK1) (Inoki et al., 2002, Potter et al., 
2002, Ma et al., 2005, Roux et a., 2004). The phosphorylation on tuberin will 
inactivate hamartin-tuberin complex thus leading to activation of mTORC1. 
 
In cells with low energy status, AMP-activated kinase (AMPK), a key sensor of 
intracellular energy status, is activated and tuberin is phosphorylated, increasing its 
GAP activity towards RHEB thus leading to inactivation of mTORC1 (Inoki et al., 
2003). 
 
In cells that lack oxygen, AMPK is activated by reduction in the level of ATP. 
AMPK activation leads to hamartin-tuberin complex stimulation thus inhibiting 
mTORC1 (Arsham et al., 2003, Liu et al., 2006). In another mechanism, hamartin-
tuberin complex is activated through transcriptional regulation of DNA damage 
response 1 (REDD1) which releases tuberin from its association with 14-3-3 protein 
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thus inhibits mTORC1 (Brugarolas et al., 2004, Reiling and Hafen, 2004 and 
DeYoung et al., 2008). 
 
In protein synthesis, the stimulation triggers the phosphorylation of ribosomal S6 
kinase (S6K1) that activates ribosomal subunit protein S6 which leads to the 
recruitment of ribosome. mTORC1 phosphorylates factor 4E binding protein-1 
(4EBP-1) causing it to permit the activity of eukaryotic translation initiation factor 
4E (eIF4E). These activations will increase protein synthesis and eventually cell 
growth (Jozwiak et al, 2005; Fingar et al., 2002 and Gingras et al., 1998). 
 
However, constant phosphorylation of S6K1 and 4EBP-1 of mTOR will cause 
unregulated cell growth and possible tumour formation or progression. This is when 
hamartin-tuberin protein complex roles into picture. In studies which investigate the 
function of hamartin-tuberin complex, findings demonstrated increased level of 
phosphorylated S6K1 and 4EBP-1 in cells that carry abnormal gene of either TSC1 
or TSC2 (Kwiatkowski et al., 2003 and Tee et al., 2002). 
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Figure 1.2: General overview of mTOR pathways. There are two distinct complexes 
which are mTORC1 and mTORC2. TSC1-TSC2 complex involves mainly in 
mTORC1 pathway (Adapted from Stern, 2010). 
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Loss of TSC1 or TSC2 had been demonstrated in cell lines and human or mouse 
tumours to indirectly increase cells vulnerability towards apoptosis. The loss caused 
stress to endoplasmic reticulum and activated the unfolded protein response which 
then mediated the negative feedback of the insulin signalling and apoptosis through 
the mTOR pathway (Ozcan et al., 2008). 
 
1.4 Genetic basis of Tuberous Sclerosis Complex 
1.4.1 TSC1 and TSC2 genes 
75-85% of the TSC cases are caused by abnormalities in either TSC1 gene or TSC2 
gene which has been identified to be disease causing and were linked to two different 
loci. These two genes have been identified by positional cloning and have been 
studied by multigenerational linkage analysis (Curatolo et al., 2003; Gomez et al., 
1999; Kandt et al., 1992 and Fryer et al., 1987). 
 
The other gene, TSC2, is located on chromosome 16p13.3 and consist of 41 exons 
which encodes a 5.5 kb mRNA. It encompasses 40 kb of genomic DNA. The gene 
encodes a different protein named tuberin (1198 kDa, 1807 amino acids) (Eur Chr 16 
TS Cons, 1993). Exons 25, 26 and 31 have been found to be the alternate splice site 
for tuberin isoform (Cheadle et al., 2000). 
 
1.4.2 Mutations Spectrum 
There are no mutation hot spots for both genes. The mutations happened at random 
location. Up to 90% of them are small mutations involving one to several nucleotides 
while the rest 10% are gross changes in the genes. Mutations that have been reported 
to be found in TSC are various, including deletion, insertion, frame-shift, missense 
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and splice-site. According to the Human Gene Mutation Database (HGMD), up until 
now there are more than 700 unique mutations have been reported in TSC2 gene 
(Stenson et al., 2014). 
 
The most common type of mutation is point mutation which contributes nearly 90% 
all mutations. Point mutation is defined as alteration in only single nucleotide that 
occurs either by deletion, substitution or insertion. Based on the functional 
characterization, point mutations are classified into nonsense mutation, missense 
mutation and silent mutation (https://www.genome.gov/glossary). 
 
Nonsense mutation introduces stop codon prematurely into the DNA sequence hence 
produces a truncated protein of either hamartin or tuberin depending upon the 
location. Missense mutation codes for different amino acid which gives rise to a 
slightly different protein with different properties of the hamartin or tuberin. Silent 
mutation codes for the same amino acid. Therefore, the protein remains unaffected 
and can retain its function normally. Insertion or deletion of nucleotides which is not 
in triplets will give more severe effect to the normal protein translation as the result 
of disturbance in the open reading frame of the gene. This type of mutation is 
specifically called frameshift mutation since it shifts the reading frame of protein 
translation hence producing a completely different type of protein from the original 
one. Insertion or deletion of nucleotide which is divisible by three is called inframe 
deletion or insertion. A codon may be missing or added but it does not cause shift in 
the triplet reading thus the protein remains the same with only one amino acid lost or 
gain (https://www.genome.gov/glossary). 
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Gross changes of the gene can either be deletion or duplication of nucleotides in 
larger scale which some time involves one or more exons. There are also cases of 
inversion mutation which involved approximately 600 kb of nucleotides of TSC2 
exon which disrupted the gene (Sampson et al., 1997). Exonic deletion is more 
common than exonic duplication. Due to deletion of some of the exons, the hamartin 
or tuberin protein will be shortened and truncated, losing the capability to carry out 
their function properly. These types of mutations occur more frequently in TSC2 
compared to TSC1 (Nellist et al., 2005 and Longa et al., 2001). 
 
A study reported that mutations occurred more in the region of exon 16 of TSC2 (Au 
et al., 2007). While in large studies, exon 16 of TSC2 gene is one of the famous spot 
along exon 32, exon 39 and exon 40, which has recorded more number of mutations 
compared to other exons (Sancak et al., 2005 and Dabora et al., 2001). 
 
As mentioned, there is no specific mutation hot-spot for the genes. However, certain 
type of mutations does occur more frequently in some domain of the gene. 
According to large studies, GAP domain on TSC2 gene is the favoured spot for 
missense type mutations (Maheswar et al., 1997 and Sancak et al., 2005). Notably, 
in-frame deletion is the most common type of mutation found in this region. 
However another report showed that only small percentage of the missense mutations 
found were located at the TSC2 GAP-domain (Au et al., 2007). These conflicting 
findings show that TSC mutations are highly variable. 
 
Different studies reported different findings on the most common mutation 
occurrence. Study by Dabora and colleagues (Dabora et al., 2001) have reported the 
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most common mutation is c.5238_5255del which occurred on TSC2 gene exon 40. 
The mutation has also been reported to be the most common in later study by Au and 
colleagues (Au et al., 2007) and a number of studies have also found the same 
mutation in their samples (Wang et al., 2013; Yao et al., 2008; Chong et al., 2006; 
Rendtorff et al., 2005 and Beauchamp et al., 1998). These six amino acids (18 
nucleotides) in-frame deletion has been identified to significantly repress ligand-
induced steroid/nuclear receptor-mediated transcription activity that results in 
uncontrolled cell growth and cell proliferation which gives rise to tissue 
malformations such as facial angiofibromas (Noonan et al., 2002). 
 
Similar 18-nucleotides deletions have also been found in two different studies that 
occurred in the same exon 40 and were located closed to one another. One happened 
at nucleotide 5256 which was reported to be the most common mutation in the study 
by Jones and colleagues while the other one happened at nucleotide 5227 (Choi et al., 
2006; Martin et al., 2003 and Jones et al., 1999). The possible cause of this type of 
deletion is slipped mispairing during replication (Cooper and Krawczak, 1993). 
Deletions which were located in the rabaptin binding site of exon 40 may disrupt the 
endocytic pathway thus contributing to TSC (Xiao et al., 1997). These data has 
shown that this type of 18 nucleotides in-frame deletion only attacked and is specific 
to exon 40 or TSC2 GAP-domain in general. 
 
Another single most common site for mutation reported in the same study by Au and 
colleagues as well as another large study by Jones and colleagues (1999), is on codon 
p.R611. There are two mutations that occurred adjacently on this site which are 
p.R611W (c.1831C>T) and p.R611Q (c.1832G>A). These mutations were likely 
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caused by spontaneous deamination of methylated cytosines that resulted in 
substitution at CpG dinucleotides in the gene sequence (Jones et al., 1999). 
According to Nellist and colleagues, both substitution mutations result in major 
conformational changes on tuberin thus interrupting its interaction with hamartin 
(Nellist et al., 2005).  The same finding was previously reported in a mutational 
study by Sancak and colleagues in 2005. It seems that the higher the number of 
samples used, the higher the probability to discover mutations distribution pattern as 
well as the most common site of mutation occurrence. 
 
Based on some of these frequently occurring mutation, distinct effects of single 
amino acid changes to tuberin on the function of the hamartin-tuberin has been 
studied. It includes the effect of tuberin amino acid changes on the tuberin-hamartin 
complex, effect on tuberin phosphorylation, effect on tuberin-dependent inhibition of 
S6K and S6 phosphorylation and effect of tuberin truncation on RHEB GTPase 
activity in vitro. The single amino acid changes studied include p.R367Q, p.N525S, 
p.K599M, p.A607T, p.609insS, p.R611Q, p.R611W, p.A614D, p.F615S, p.C696Y, 
p.V769E, p.L826M, p.R905Q, p.P1202H and p.G1556S. Only three of the amino 
acid changes, p.R367Q, p.A607T and p.L826M did not give any effect on tuberin-
hamartin formation, inhibition S6K or S6 phosporylation or the stimulation of RHEB 
GTPase activity while the rest of the changes appeared pathogenic. p.R611Q, 
p.R611W, p.A614D, p.C696Y and p.V769E have been identified to inactivate 
tuberin completely in all of the essays conducted. These substitutions are said to 
cause major conformational changes to the protein (Nellist et al., 2005). 
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Nellist and colleagues studied two more changes which are p.609insS and p.F615S 
and found out that these changes destroyed the interaction of hamartin and tuberin, 
prevented tuberin phosphorylation by PKB and prevented S6K phosphorylation 
inhibiton. However, the tuberin inactivation by these changes was incomplete and 
they still have some RHEB GAP activity along partial inhibition of S6 
phosphorylation. Changes denoted as p.R905Q, p.P1202H, p.G1556S, p.N525S and 
p.K599M which were also studied did not show any pathogenic effects (Nellist et al., 
2005). 
 
Some studies have also reported a small portion of somatic mosaicism in TSC cases. 
Somatic mosaicism happens when some of the cells in the body carry the TSC 
mutation while some other cells carry the normal TSC gene. A large study by 
Kozlowski and colleagues in 2006 involved 261 patients has reported eight cases of 
somatic mosaicism (Kozlowski et al., 2006). In another large study involving 224 
patients, two patients have been suspected to have been the case of somatic 
mosaicism (Dabora et al., 2001). 
 
Another common phenomenon in TSC cases is loss of heterozygosity. Every somatic 
cell has two normal copies of TSC genes. The genes are said to be in heterozygous 
state when one copy of the allele has already been affected (either due to inherited or 
de novo mutation), leaving only one functional copy of the gene. In this state, the 
remaining normal copy of the gene is capable of compensating the loss of the mutant 
copy of the gene. Loss of heterozygosity comes into picture when the only normal 
copy of the gene is also affected, losing both normal copies, thus resulting in the 
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inactivation of the gene. Without the presence of the normal gene, TSC disease will 
develop. 
 
A number of studies have shown that frequency of loss of heterozygosity is high in 
TSC tubers, especially in renal angiomyolipomas than neurological tumours (Niida et 
al., 2001; Au et al., 1999 and Henske et al., 1997). One possible reason is that 
inactivation of both copies of the gene may not be necessary for the pathogenesis of 
some TSC tumours (Tucker and Friedman, 2002). Loss of heterozygosity is also 
evidence that TSC1 and TSC2 work together as a tumour suppressor gene where loss 
of heterozygosity can be on either one gene for the disease to be developed. 
 
Despite the numerous mutations found, all studies have reported that there are a 
small portion of the clinically diagnosed TSC patients that showed negative result for 
the mutational analysis. These patients with no identifiable mutation generally 
developed milder symptom compared to patients that have been detected to have 
mutation either in TSC1 or TSC2 gene (Dabora et al., 2001, Sancak et al., 2005 and 
Au et al., 2008). 
 
1.5 Epidemiology of Tuberous Sclerosis Complex 
The prevalence of TSC was reported to be one case in approximately 6000 births 
(Osborne et al., 1991). Worldwide, TSC affects about one to two million people 
while in United States, it affects as many as 25 000 to 40 000 people. TSC has no 
ethnic, gender and race preference (National Institute of Neurological Disorders and 
Stroke, 2014).  Up to two-thirds of the cases are sporadic while the rest of the cases 
are familial. Being autosomal dominant in nature, only one affected parent with 
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mutant gene is needed to pass down TSC to an offspring with 50% chance of 
developing TSC. However, the offspring may not present the same manifestations as 
the parent even with the same type of mutation. 
 
Many cases remain undiagnosed in previous years. However, more cases even with 
milder manifestations are now being diagnosed attributed to significant progress in 
TSC researches as well as development of TSC diagnosis technologies. The 
prevalence was expected to go higher in near future.  
 
In many developing countries like in Malaysia, data on the prevalence of TSC is 
absent. However, there has been no indication that TSC occur more frequently in 
certain geographic locations over the other, nor within certain ethnicities over the 
other. It is therefore reasonable to suggest that TSC may occur in the same 
prevalence rate as that reported above.  
 
1.5.1 Tuberous Sclerosis Complex and ethnicity 
Mutational studies have been carried out in European, American and Asian 
counterparts (Taiwanese, Chinese Han, Japanese and Korean). All the studies have 
reported almost similar mutations distribution among the populations involved in the 
studies. Some population such as Korean represented lower mutations distribution 
compared to Western countries and Japan but no correlation between ethnicity and 
higher frequency of TSC mutations was observed (Choi et al., 2006). 
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1.5.2 Tuberous Sclerosis Complex and gender 
The chance for male TSC patient to have mental retardation is higher compared to 
female patient. The male patients are likely to have renal cysts, retinal and skin 
lesions more. The observable different manifestations seen in male and female 
patients are best explained by the different hormones produced by male and female 
body. Sex hormones have been illustrated to influence the progression of TSC 
manifestations in human as well as in animal models (Sancak et al., 2005).  
 
1.5.3 Familial versus sporadic cases 
One of the aspects to be looked at is the comparison between familial cases and 
sporadic cases. Clinical manifestations in familial cases were reported to be lower 
and milder than in the sporadic cases. Skin manifestations, mental retardation and 
renal cysts are significantly more common in sporadic cases (Au et al., 2007; Choi et 
al., 2006 and Jones et al., 1999). Seizures and onset age of seizures, SEGAs, and 
number of cortical tubers were also low in familial cases (Choi et al., 2006). A large 
study by Sancak and colleagues has also reported the same findings and in addition, 
they found a significantly higher occurrence of SEN and retinal phakomas. They also 
found out that hypomelanotic macules was significantly higher in familial cases 
(Sancak et al., 2005). 
 
In familial cases, the affected parent (either mother or father) of the affected patient 
are highly likely to have the same mutation in the gene though the clinical 
manifestations might be different. There was a case with the same mutation found in 
monozygotic twins but only one of them was diagnosed to have shagreen patch and 
cardiac rhabdomyoma (Martin et al., 2003). Another study by Sasongko and 
